Barbara N DeRatt1, Maria A Ralat1, Vegard Lysne2, Fariba Tayyari3,4, Indu Dhar2, Arthur S Edison3,4, Timothy J Garrett5, Øivind Midttun6, Per Magne Ueland2,7, Ottar Kjell Nygård2,8, Jesse F Gregory9. 1. Departments of Food Science and Human Nutrition and. 2. Department of Clinical Science, University of Bergen, Bergen, Norway. 3. Departments of Biochemistry and. 4. Genetics, Institute of Bioinformatics, and Complex Carbohydrate Research Center, University of Georgia, Athens, GA. 5. Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL. 6. Bevital AS, Bergen, Norway. 7. Laboratory of Clinical Biochemistry and. 8. Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. 9. Departments of Food Science and Human Nutrition and jfgy@ufl.edu.
Abstract
Background: An elevated circulating cystathionine concentration, which arises in part from insufficiencies of vitamin B-6, B-12, or folate, has been shown to be associated with cardiovascular disease (CVD) risk. Hydrogen sulfide (H2S) is a gasotransmitter involved in vasodilation, neuromodulation, and inflammation. Most endogenously produced H2S is formed by pyridoxal phosphate (PLP)-dependent enzymes by noncanonical reactions of the transsulfuration pathway that yield H2S concurrently form lanthionine and homolanthionine. Thus, plasma lanthionine and homolanthionine concentrations can provide relative information about H2S production in vivo.Objective: To determine the metabolic consequences of an elevated plasma cystathionine concentration in adults with stable angina pectoris (SAP), we conducted both targeted and untargeted metabolomic analyses. Methods: We conducted NMR and LC-mass spectrometry (MS) metabolomic analyses on a subset of 80 plasma samples from the Western Norway Coronary Angiography Cohort and selected, based on plasma cystathionine concentrations, a group with high cystathionine concentrations [1.32 ± 0.60 μmol/L (mean ± SD); n = 40] and a group with low cystathionine concentrations [0.137 ± 0.011 μmol/L (mean ± SD); n = 40]. Targeted and untargeted metabolomic analyses were performed and assessed with the use of Student's t tests corrected for multiple testing. Overall differences between the cystathionine groups were assessed by untargeted NMR and LC-MS metabolomic methods and evaluated by partial least squares discriminant analysis (PLS-DA) with significant discriminating metabolites identified with 99% confidence. Results: Subjects with high cystathionine concentrations had 75% higher plasma lanthionine concentrations (0.12 ± 0.044 μmol/L) than subjects with low cystathionine concentrations [0.032 ± 0.013 μmol/L (P < 0.001)]. Although plasma homolanthionine concentrations were notably higher than lanthionine concentrations, they were not different between the groups (P = 0.47). PLS-DA results showed that a high plasma cystathionine concentration in SAP was associated with higher glucose, branched-chain amino acids, and phenylalanine concentrations, lower kidney function, and lower glutathione and plasma PLP concentrations due to greater catabolism. The high-cystathionine group had a greater proportion of subjects in the postprandial state. Conclusion: These data suggest that metabolic perturbations consistent with higher CVD risk exist in SAP patients with elevated plasma cystathionine concentrations.
Background: An elevated circulating cystathionine concentration, which arises in part from insufficiencies of vitamin B-6, B-12, or folate, has been shown to be associated with cardiovascular disease (CVD) risk. Hydrogen sulfide (H2S) is a gasotransmitter involved in vasodilation, neuromodulation, and inflammation. Most endogenously produced H2S is formed by pyridoxal phosphate (PLP)-dependent enzymes by noncanonical reactions of the transsulfuration pathway that yield H2S concurrently form lanthionine and homolanthionine. Thus, plasma lanthionine and homolanthionine concentrations can provide relative information about H2S production in vivo.Objective: To determine the metabolic consequences of an elevated plasma cystathionine concentration in adults with stable angina pectoris (SAP), we conducted both targeted and untargeted metabolomic analyses. Methods: We conducted NMR and LC-mass spectrometry (MS) metabolomic analyses on a subset of 80 plasma samples from the Western Norway Coronary Angiography Cohort and selected, based on plasma cystathionine concentrations, a group with high cystathionine concentrations [1.32 ± 0.60 μmol/L (mean ± SD); n = 40] and a group with low cystathionine concentrations [0.137 ± 0.011 μmol/L (mean ± SD); n = 40]. Targeted and untargeted metabolomic analyses were performed and assessed with the use of Student's t tests corrected for multiple testing. Overall differences between the cystathionine groups were assessed by untargeted NMR and LC-MS metabolomic methods and evaluated by partial least squares discriminant analysis (PLS-DA) with significant discriminating metabolites identified with 99% confidence. Results: Subjects with high cystathionine concentrations had 75% higher plasma lanthionine concentrations (0.12 ± 0.044 μmol/L) than subjects with low cystathionine concentrations [0.032 ± 0.013 μmol/L (P < 0.001)]. Although plasma homolanthionine concentrations were notably higher than lanthionine concentrations, they were not different between the groups (P = 0.47). PLS-DA results showed that a high plasma cystathionine concentration in SAP was associated with higher glucose, branched-chain amino acids, and phenylalanine concentrations, lower kidney function, and lower glutathione and plasma PLP concentrations due to greater catabolism. The high-cystathionine group had a greater proportion of subjects in the postprandial state. Conclusion: These data suggest that metabolic perturbations consistent with higher CVD risk exist in SAP patients with elevated plasma cystathionine concentrations.
Authors: K Robinson; K Arheart; H Refsum; L Brattström; G Boers; P Ueland; P Rubba; R Palma-Reis; R Meleady; L Daly; J Witteman; I Graham Journal: Circulation Date: 1998-02-10 Impact factor: 29.690
Authors: Steven R Davis; Jennifer B Scheer; Eoin P Quinlivan; Bonnie S Coats; Peter W Stacpoole; Jesse F Gregory Journal: Am J Clin Nutr Date: 2005-03 Impact factor: 7.045
Authors: James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer Journal: JAMA Date: 2004-02-04 Impact factor: 56.272
Authors: David S Wishart; Dan Tzur; Craig Knox; Roman Eisner; An Chi Guo; Nelson Young; Dean Cheng; Kevin Jewell; David Arndt; Summit Sawhney; Chris Fung; Lisa Nikolai; Mike Lewis; Marie-Aude Coutouly; Ian Forsythe; Peter Tang; Savita Shrivastava; Kevin Jeroncic; Paul Stothard; Godwin Amegbey; David Block; David D Hau; James Wagner; Jessica Miniaci; Melisa Clements; Mulu Gebremedhin; Natalie Guo; Ying Zhang; Gavin E Duggan; Glen D Macinnis; Alim M Weljie; Reza Dowlatabadi; Fiona Bamforth; Derrick Clive; Russ Greiner; Liang Li; Tom Marrie; Brian D Sykes; Hans J Vogel; Lori Querengesser Journal: Nucleic Acids Res Date: 2007-01 Impact factor: 16.971
Authors: Jesse F Gregory; Youngja Park; Yvonne Lamers; Nirmalya Bandyopadhyay; Yueh-Yun Chi; Kichen Lee; Steven Kim; Vanessa da Silva; Nikolas Hove; Sanjay Ranka; Tamer Kahveci; Keith E Muller; Robert D Stevens; Christopher B Newgard; Peter W Stacpoole; Dean P Jones Journal: PLoS One Date: 2013-06-11 Impact factor: 3.240
Authors: Indu Dhar; Gard F T Svingen; Per M Ueland; Vegard Lysne; Mads M Svenningsson; Grethe S Tell; Ottar K Nygård Journal: J Am Heart Assoc Date: 2018-09-04 Impact factor: 5.501
Authors: Alexander T Limkakeng; Ricardo Henao; Deepak Voora; Thomas O'Connell; Michelle Griffin; Ephraim L Tsalik; Svati Shah; Christopher W Woods; Geoffrey S Ginsburg Journal: PLoS One Date: 2019-02-01 Impact factor: 3.240